Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Fusion Antibody (FAB)

Price 3.75p on 19-04-2024 at 16:30:02
Change 0.00p 0%
Buy 3.80p
Sell 3.70p
Buy / Sell FAB Shares
Last Trade: Buy 26.00 at 3.80p
Day's Volume: 138,126
Last Close: 3.75p
Open: 3.80p
ISIN: GB00BDQZGK16
Day's Range 3.75p - 3.80p
52wk Range: 3.10p - 50.00p
Market Capitalisation: £4m
VWAP: 3.789407p
Shares in Issue: 95m

Recent Trades History Fusion Antibody (FAB)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 26 3.80p Ordinary
15:29:14 - 19-Apr-24
Buy* 26 3.80p Ordinary
15:28:23 - 19-Apr-24
Buy* 30,567 3.795p Ordinary
15:05:04 - 19-Apr-24
Buy* 93,512 3.788p Ordinary
14:50:50 - 19-Apr-24
Buy* 26 3.80p Ordinary
14:23:34 - 19-Apr-24
Buy* 13,087 3.78999p Ordinary
13:43:26 - 19-Apr-24
Buy* 26 3.80p Ordinary
13:12:28 - 19-Apr-24
Sell* 250 3.70p SI Trade
12:39:13 - 19-Apr-24
Buy* 47 3.80p Ordinary
11:51:48 - 19-Apr-24
Buy* 26 3.80p Ordinary
09:13:50 - 19-Apr-24

Share Price History for Fusion Antibody

Time period:
to
Date Open High Low Close Volume

Share News for Fusion Antibody

Fusion Antibodies inks commercial contract for OptiPhage library

15th Apr 2024 13:29

(Alliance News) - Fusion Antibodies PLC on Monday said that it has signed a commercial contract to develop an OptiPhage library for a non-human antibody species. Read More

TRADING UPDATES: Sondrel wins USD23 million contract

27th Feb 2024 14:18

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: Fusion Antibodies raises GBP1.4 million via placing

14th Feb 2024 11:27

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Conditionally raises GBP1.4 million before expenses via placing of 34.4 million shares at 4 pence each. The issue price represents a discount of 5.9% to Fusion's closing mid-market share price on Tuesday. Further, it intends to issue 1.5 million new shares to certain directors in lieu of or in satisfaction of salary and fees due to them and which shall be issued immediately following publication of its announcement. Also intends to grant a total of up to 3.8 million new share options to staff and senior management. Read More

Fusion Antibodies strikes follow-on research and development project

6th Feb 2024 11:48

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has won a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company". Read More

AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations

6th Feb 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More

FTSE 100 Latest
Value7,895.85
Change18.80

Login to your account

Forgot Password?

Not Registered